These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37858338)

  • 1. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
    Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
    Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.
    Visser M; Papillon JPN; Luzzio M; LaMarche MJ; Fan J; Michael W; Wang D; Zhang A; Straub C; Mathieu S; Kato M; Palermo M; Chen C; Ramsey T; Joud C; Barrett R; Vattay A; Guo R; Bric A; Chung F; Liang G; Romanowski MJ; Lam J; Thohan S; Atassi F; Wylie A; Cooke VG
    J Med Chem; 2024 Jan; 67(2):1447-1459. PubMed ID: 38198520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
    Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
    Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
    Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
    Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
    Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
    Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches].
    Zhilnikova MV; Troitskaya OS; Novak DD; Atamanov VV; Koval OA
    Mol Biol (Mosk); 2024; 58(2):189-203. PubMed ID: 39355878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
    Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
    Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
    Musi E; Ambrosini G; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
    Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
    Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS
    Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
    Sagoo MS; Harbour JW; Stebbing J; Bowcock AM
    Oncogene; 2014 Sep; 33(39):4722-3. PubMed ID: 24413085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
    Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
    Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
    Ambrosini G; Sawle AD; Musi E; Schwartz GK
    Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
    Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
    Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.
    Arang N; Lubrano S; Rigiracciolo DC; Nachmanson D; Lippman SM; Mali P; Harismendy O; Gutkind JS
    J Biol Chem; 2023 Feb; 299(2):102866. PubMed ID: 36596361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.